BVIZ Vice President from Regensburg reelected

In Germany there are currently over 350 technology and startup centers (TGZ) active, which together in the last year have provided consultancy services to a total of 4,420 startups and 12,060 companies with a total of 83,320 jobs on their premises. Half of this is organized at BVIZ with headquarters in Berlin, which was founded exactly 30 years ago in 1988 with 23 centers. In his address at the 30 year anniversary of the association Peter Altmaier, Federal Minister for Economic Affairs and Energy (BMWI) emphasized the significance of the TGZ. The TGZ helps young and innovative companies in the difficult starting years with experience, contacts and know-how. It thereby significantly raises the degree of innovation in Germany and makes startups far easier. To date in the last 30 years an astonishing 43,470 companies were able to be successfully founded and a total of 277,400 jobs created (see figure in the attachment). Furthermore for three decades the BVIZ has worked hard to improve the startup and innovation structure in Germany. In doing so the BVIZ and the centers make an important contribution to the German economy, emphasized Altmaier, as the startups of today will be the medium sized companies of tomorrow.

 

At the general meeting of the association Dr. Diefenthal was elected unanimously as vice president of the BVIZ. BioPark Regensburg GmbH has been a member of the association since 2006. In 2009 Dr. Diefenthal was elected as spokesperson for the BioPark working group at the BVIZ. Since 2011 he has been a member of the board and since 2014 vice president of the association. “I am pleased to bring now almost 20 years of expertise from the BioPark in Regensburg to the association and to always learn something through the lively exchange with colleagues in the working groups, meetings behind closed doors and workshops”, commented Dr. Diefenthal on his reelection. “A further function of the board is to advise decision makers in politics at federal, state and regional levels on the themes of startup funding and development of technology”, explained Dr. Diefenthal. In biotechnology the framework conditions and requirements made to the TGZ and startups are relatively high. In addition to expensive and state-of-the-art laboratory infrastructure many biotech companies need to take a deep breath in the financing and implementation of their business ideas due to the long years of clinical trials. “This distinguishes startups in the biotech scene from classical startups, for example from the IT scene, who mostly require office premises and short development periods, and are thereby more quickly on the market and can rapidly generate their own cash flow.